Entero Therapeutics, Inc. (NASDAQ:ENTO – Get Free Report) was the target of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 152,900 shares, an increase of 62.7% from the October 31st total of 94,000 shares. Based on an average daily volume of 395,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 3.3% of the company’s shares are sold short.
Entero Therapeutics Price Performance
ENTO stock traded up $0.02 during mid-day trading on Friday, hitting $0.47. 25,201 shares of the company were exchanged, compared to its average volume of 174,591. Entero Therapeutics has a 12-month low of $0.19 and a 12-month high of $14.51. The firm’s fifty day simple moving average is $0.52.
Entero Therapeutics (NASDAQ:ENTO – Get Free Report) last posted its quarterly earnings data on Monday, October 21st. The company reported ($3.37) earnings per share for the quarter. Sell-side analysts anticipate that Entero Therapeutics will post -1.13 EPS for the current fiscal year.
Entero Therapeutics Company Profile
Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.
Featured Articles
- Five stocks we like better than Entero Therapeutics
- 3 REITs to Buy and Hold for the Long Term
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- Stock Splits, Do They Really Impact Investors?
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- How to Start Investing in Real Estate
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.